Insider · SEC Form 4 filer
Richard Pfenniger
Companies
Where they file as an insider
GeneDx (WGS) Director Latest filing Jun 18, 2026
Fluent (FLNT) Director Latest filing Jun 17, 2026
Cocrystal Pharma (COCP) Director Latest filing Oct 28, 2025
Asensus Surgical (ASXC) Director Latest filing Aug 22, 2024
Opko Health (OPK) Director Latest filing Jan 5, 2024
Track record
Did their buys beat the typical stock?
Open-market buys7
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check0
Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.
Opko Health (OPK) Bought Jan 5, 2024 · $23.5K · 25,000 shares Beat typical Mar 31, 2024 $1.20 → Sep 30, 2024 $1.49 · +24.2% (typical stock +3.2%)
Opko Health (OPK) Bought Nov 13, 2023 · $32.5K · 25,000 shares Behind typical Dec 31, 2023 $1.51 → Jun 30, 2024 $1.25 · −17.2% (typical stock −1.2%)
GeneDx (WGS) Bought Nov 8, 2023 · $14.9K · 10,000 shares Not counted Not counted. We have no fund price for this stock on both Dec 31, 2023 and Jun 30, 2024.
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.